CONSTANCE HARTHCOCK: Open Payments
NPI 1841665494 · BRANDON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,418 in 80 payments from 17 companies in 2025. Trend: 2023 $364 · 2024 $1,669 · 2025 $1,418
Food & beverage: $1,418
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $247 |
| Novo Nordisk Inc | 12 | $188 |
| Corcept Therapeutics | 9 | $178 |
| GlaxoSmithKline, LLC. | 9 | $163 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $103 |
| AstraZeneca Pharmaceuticals LP | 5 | $92 |
| Lilly USA, LLC | 4 | $85 |
| Esperion Therapeutics, Inc. | 4 | $77 |
| PFIZER INC. | 3 | $69 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $58 |
Products named: Korlym, TRELEGY ELLIPTA, VRAYLAR, Kerendia, FARXIGA, NEXLETOL, UBRELVY, Ozempic.
Industry payments across MS — which companies pay providers there.
